These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations. Nwabufo CK Cancer Chemother Pharmacol; 2024 Feb; 93(2):89-105. PubMed ID: 37594572 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gilbert L; Oaknin A; Matulonis UA; Mantia-Smaldone GM; Lim PC; Castro CM; Provencher D; Memarzadeh S; Method M; Wang J; Moore KN; O'Malley DM Gynecol Oncol; 2023 Mar; 170():241-247. PubMed ID: 36736157 [TBL] [Abstract][Full Text] [Related]
5. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227 [TBL] [Abstract][Full Text] [Related]
7. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463 [TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates for ovarian cancer: current clinical development. Stewart D; Cristea M Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis. Wang Y; Liu L; Jin X; Yu Y Crit Rev Oncol Hematol; 2024 Feb; 194():104230. PubMed ID: 38122916 [TBL] [Abstract][Full Text] [Related]
10. Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer. Gonzalez-Ochoa E; Veneziani AC; Oza AM Clin Med Insights Oncol; 2023; 17():11795549231187264. PubMed ID: 37528890 [TBL] [Abstract][Full Text] [Related]
11. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Moore KN; Vergote I; Oaknin A; Colombo N; Banerjee S; Oza A; Pautier P; Malek K; Birrer MJ Future Oncol; 2018 Jul; 14(17):1669-1678. PubMed ID: 29424243 [TBL] [Abstract][Full Text] [Related]
12. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Vergote I; Ponte JF; Birrer MJ Future Oncol; 2018 Jan; 14(2):123-136. PubMed ID: 29098867 [TBL] [Abstract][Full Text] [Related]
13. ADC: a deadly killer of platinum resistant ovarian cancer. Cheng X; Li P; Jiang R; Meng E; Wu H J Ovarian Res; 2024 Oct; 17(1):196. PubMed ID: 39367438 [TBL] [Abstract][Full Text] [Related]
14. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer. Kokori E; Olatunji G; Komolafe R; Abraham IC; Ukoaka B; Samuel O; Ayodeji A; Ogunbowale I; Ezenwoba C; Aderinto N Medicine (Baltimore); 2024 May; 103(20):e38132. PubMed ID: 38758856 [TBL] [Abstract][Full Text] [Related]
15. Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial. Coleman RL; Lorusso D; Oaknin A; Cecere SC; Denys H; Colombo N; van Gorp T; Konner JA; Romeo Marin M; Harter P; Murphy C; Wang Y; Esteves B; Method M; Matulonis U Int J Gynecol Cancer; 2024 Aug; 34(8):1119-1125. PubMed ID: 38858103 [TBL] [Abstract][Full Text] [Related]
16. Advances in antibody-drug conjugates for gynecologic malignancies. Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278 [TBL] [Abstract][Full Text] [Related]
17. Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer. El Bairi K; Al Jarroudi O; Afqir S Semin Cancer Biol; 2021 Dec; 77():42-55. PubMed ID: 33812984 [TBL] [Abstract][Full Text] [Related]
18. The evolving landscape of antibody-drug conjugates in gynecologic cancers. Tolcher A; Hamilton E; Coleman RL Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499 [TBL] [Abstract][Full Text] [Related]
19. Mirvetuximab Soravtansine: First Approval. Heo YA Drugs; 2023 Feb; 83(3):265-273. PubMed ID: 36656533 [TBL] [Abstract][Full Text] [Related]
20. Integrating antibody drug conjugates in the management of gynecologic cancers. Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]